Get notified when CRBP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Dilution Per Share to New Investors In This Offering: $2.46 (new) — New investors will experience immediate dilution of $2.46 per share, representing a significant gap between the offering price and net tangible book value per share.
- 1,025,000 Pre-funded Warrants Outstanding At $0.0001 Exercise Price (new) — The company has 1,025,000 pre-funded warrants with a nominal exercise price, effectively equivalent to common stock, which will cause significant dilution when exercised.
Corbus Pharmaceuticals launches up to $127.5M at-the-market offering; shares priced at market, $9.40 reference
Filed August 7, 2026 · ~2 min read
Key Changes
-
high
Corbus may sell up to $127.5M of common stock in an at-the-market offering through Jefferies, with shares sold at prevailing market prices.
The Offering verify on EDGAR → -
high
Implied post-offering market capitalization is $310.0M, based on 32,974,034 shares outstanding at the $9.40 reference price.
The Offering verify on EDGAR → -
medium
Net proceeds fund development of CRB-701, CRB-913, other pre-clinical compounds, and general corporate purposes; no specific allocation amounts are set.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
Partner
Trade CRBP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify